Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;32(7):775-9.
doi: 10.1080/13803390903521018. Epub 2010 Feb 24.

Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease

Affiliations

Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease

Roy N Alcalay et al. J Clin Exp Neuropsychol. 2010 Aug.

Abstract

While little is known about risk factors for cognitive impairment in early onset Parkinson disease (EOPD), postmortem studies have shown an association between dementia with Lewy bodies (DLB) and glucocerebrosidase (GBA) mutation. We compared Mini-Mental State Examination (MMSE) performance and self-reported cognitive impairment in 699 EOPD participants genotyped for mutations in parkin (PRKN), leucine-rich repeat kinase-2 (LRRK2), and GBA. Logistic regression was used to assess the association between reported cognitive impairment and MMSE score, as well as between GBA group membership and self-reported impairment and MMSE. GBA carriers reported more impairment, but MMSE performance did not differ among genetic groups. Detailed neuropsychological testing is required to explore the association between cognitive impairment and GBA mutations.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors report no conflicts of interest.

References

    1. Acion L, Peterson JJ, Temple S, Arndt S. Probabilistic index: An intuitive non-parametric approach to measuring the size of treatment effects. Statistics in Medicine. 2006;25(4):591–602. - PubMed
    1. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson’s disease. Neurology. 1993;43(6):1150–1158. - PubMed
    1. Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, et al. Case-control study of the parkin gene in early-onset Parkinson disease. Archives of Neurology. 2006a;63(4):548–552. - PubMed
    1. Clark LN, Haamer E, Mejia-Santana H, Harris J, Lesage S, Durr A, et al. Construction and validation of a Parkinson’s disease mutation genotyping array for the Parkin gene. Movement Disorders. 2007a;22(7):932–937. - PubMed
    1. Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Archives of Neurology. 2009;66(5):578–583. - PMC - PubMed

Publication types

MeSH terms

Substances